📈 Stocks
BioMarin and Ascendis Resolve Patent Dispute, Shares Rally 5% on Settlement
(just now)
BioMarin and Ascendis settle a global patent dispute over the drug Yuviwel, with BioMarin securing a 20% US royalty stream and Ascendis…